Compare SATL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATL | NTLA |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | 154 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.8B |
| IPO Year | N/A | 2016 |
| Metric | SATL | NTLA |
|---|---|---|
| Price | $7.12 | $13.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 23 |
| Target Price | $5.50 | ★ $20.02 |
| AVG Volume (30 Days) | ★ 9.3M | 5.4M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | $88.89 | N/A |
| Revenue Next Year | $56.98 | $62.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $1.26 | $7.95 |
| 52 Week High | $12.00 | $28.24 |
| Indicator | SATL | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 48.40 |
| Support Level | $6.13 | $11.71 |
| Resistance Level | $8.18 | $14.02 |
| Average True Range (ATR) | 0.93 | 1.03 |
| MACD | -0.39 | 0.10 |
| Stochastic Oscillator | 0.68 | 37.70 |
Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.